Adaptive Biotechnologies Corporation Common Stock (ADPT) Stock Price
ADPTStock
$24.02+39.09%52W
Market Cap$3.83B
P/E—
PEG Ratio—
Div yield—
Beta2.17
ADPT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)55.41%
Price vs S&P 500 (4W)-12.46%
VGM Score59.40
ADPT Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.13 | -$0.25 | -87.20%(-$0.12) | |
| Q1 2026 | -$0.16 | -$0.13 | +20.18%(+$0.03) | |
| Q4 2025 | -$0.18 | -$0.09 | +50.78%(+$0.09) | |
| Q3 2025 | -$0.14 | $0.06 | +143.30%(+$0.20) | |
| Q2 2025 | -$0.24 | -$0.17 | +28.57%(+$0.07) |
ADPT Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.21
4.21
4.21
4.21
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
ADPTAdaptive Biotechnologies Corporation Common Stock | D | B | B | 12.4x | 50.1% | 75.6% | — | $24.02 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Adaptive Biotechnologies Corporation Common Stock
Adaptive Biotechnologies develops diagnostic tests that leverage the adaptive immune system to detect and monitor cancer. The company's flagship product, clonoSEQ, is FDA-authorized for minimal residual disease monitoring in patients with multiple myeloma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. The test is also available as a CLIA-validated service for other lymphoid malignancies, including diffuse large B-cell lymphoma.